Animal intervention study

Therapeutic Effect of Nicotinamide Mononucleotide for Hypoxic–Ischemic Brain Injury in Neonatal Mice

Takuya Kawamura et al. · ASN Neuro · 2023

Evidence type: Preclinical mechanistic study Interpretive weight: Mechanistic contextResearch area: Neonatal hypoxic–ischemic brain injury
DesignRandomized-within-litter, blinded preclinical neonatal mouse hypoxia–ischemia intervention with acute biochemical, histologic, developmental, motor, and memory assessments.
PopulationPostnatal-day-9 male and female mice exposed to unilateral carotid ligation and hypoxia; naïve animals provided reference values.
SampleVaried by endpoint, generally 6–21 mice per group; main long-term behavioral groups were approximately 18–21 per group
InterventionA single intraperitoneal NMN dose immediately after hypoxia–ischemia; 50, 150, and 300 mg/kg were used in dose-ranging work and 50 mg/kg in the main long-term experiments, versus saline.
EndpointsHippocampal NAD+, SIRT1, and SIRT6; Caspase-3 activity and HMGB1 release; Brain tissue loss and neuroinflammation; Early developmental behavior; Motor and memory function at approximately six weeks

What the publication reported

Newborn mice were exposed to an experimental form of hypoxic–ischemic brain injury and received NMN by injection immediately afterward. NMN restored selected NAD-related measures, reduced markers of cell injury and inflammation, limited tissue loss, and improved several later behavioral tests. These results are mechanistic animal evidence only and do not demonstrate safety or benefit in human infants.

Key findings

Hypoxia–ischemia reduced hippocampal NAD+ and SIRT6 and increased HMGB1 release. NMN restored NAD+ and SIRT6, reduced caspase-3 activity and HMGB1 release, and reduced later tissue loss and neuroinflammation. Treated mice performed better on early developmental measures and later motor and memory tests. SIRT1 was not reduced by injury in the same way as SIRT6, and the exact pathway linking NMN to HMGB1 remained unresolved.

What it cannot establish

This was a neonatal mouse model, not a human trial. NMN was injected immediately after a standardized experimental injury, which differs from oral use and real-world treatment timing. The study did not combine NMN with therapeutic hypothermia. Sample sizes varied across endpoints, and mechanistic assays cannot establish human clinical benefit, optimal dose, safety, or compatibility with standard care.

HealthspanX claim boundary: This mouse study does not show that oral NMN benefits healthy adults or infants, treats human neonatal brain injury, replaces standard care, or predicts outcomes for HealthspanX Ultra Pure NMN.

Continue reviewing

Return to the complete evidence library.

Evidence Center Ultra Pure NMN